Barr Pharmaceuticals is making a second attempt at getting the FDA to approve its morning-after Plan B contraceptive drug for over-the-counter sales by limiting such sales to women at least 16 years old. The plan submitted to the agency is an attempt to overturn the agency's May ruling against OTC sales of Plan B.

Related Summaries